NAD+ Supplement Side Effects: What to Expect

The short answer

At the doses used in human trials, NAD+ precursor supplements (NMN and nicotinamide riboside) have a mild side effect profile: nausea, flushing, stomach upset, headache and, in a minority of people, muscle cramps or sleep disruption. Trials of NR up to 2 g a day and NMN up to 900 mg a day for two to three months have not reported serious adverse events. What the trials cannot tell you is what happens over years, because none has run that long. The unresolved questions are not about tolerability. They are about methylation load, about what raising NAD+ does to a tumor that is already there, and, for injected and infused NAD+, about infusion reactions that are common enough to be part of how clinics run the drip.

Which “NAD supplement” are we talking about?

The phrase covers four different things, and the side effects differ by route. Swallowed NAD+ itself is not effectively absorbed and is mostly broken down in the gut, so its side effects are essentially those of a vitamin B3 dose. Liposomal oral NAD+ is being researched and its absorption is unclear. Injected NAD+, by IV infusion or subcutaneous injection, is the well-established route for delivering the molecule itself and has its own reaction profile. And the precursors, NMN and NR, are what most people mean by an NAD+ supplement. The routes are compared in the NAD+ pillar. This article takes the precursors first, because they have the trial data, then covers oral NAD+ and the injected routes.

What the trials recorded

Compound and trial	Dose and duration	Adverse events reported
NR, Martens 2018, Nat Commun	1 g/day, 6 weeks, crossover in 24 adults	Well tolerated; nausea, flushing, leg cramps and muscle soreness reported by a few participants on NR, comparable to placebo
NR, Dollerup 2018, Am J Clin Nutr	2 g/day, 12 weeks, 40 obese men	No serious adverse events; no metabolic benefit either
NR, Elhassan 2019, Cell Reports	1 g/day, 21 days, older men	Well tolerated; NAD+ metabolome rose; a shift toward lower circulating inflammatory markers
NR, Conze 2019, Sci Rep	100, 300 or 1,000 mg/day, 8 weeks, 140 adults	No difference in adverse events from placebo at any dose
NMN, Yi 2023, GeroScience	300, 600 or 900 mg/day, 60 days, 80 adults	No serious adverse events; laboratory safety measures unchanged
NMN, Okabe 2022, Front Nutr	250 mg/day, 12 weeks, healthy adults	No notable adverse events; no changes in liver, kidney or blood measures
NMN, Yoshino 2021, Science	250 mg/day, 10 weeks, 25 women	No adverse events attributed to NMN

⚠ CLAIM (wellness): Randomized trials of nicotinamide riboside up to 2 g per day and NMN up to 900 mg per day, lasting up to 12 weeks, have not reported serious adverse events, and rates of mild side effects were generally similar to placebo. No trial has assessed safety beyond a few months. Basis: Martens 2018; Dollerup 2018; Conze 2019; Yi 2023; Okabe 2022. Lane: educational.

Two features of that table deserve attention. First, the doses are high relative to what most products supply, so tolerability at shelf doses is if anything better supported than the table suggests. Second, every trial is short. The longest published NR study is a five-month trial in twins, and nothing on NMN exceeds three months. “No serious adverse events in 12 weeks” is a real and reassuring finding, and it is also the only kind of finding that exists.

The common, mild effects

• Nausea and stomach upset. The most frequent complaint with both precursors, usually in the first week, usually improved by taking the dose with food.
• Flushing. Warmth or redness of the face and upper body. Much less common than with niacin (nicotinic acid), which causes flushing in most people, because NR and NMN are not converted to nicotinic acid. It does happen, particularly at higher doses.
• Headache. Reported in trials at rates close to placebo, and in community reports at higher rates than that.
• Muscle cramps and soreness. Recorded with 1 g NR in the Martens trial in a few participants. Mechanism unknown.
• Fatigue. Paradoxically, a subset of people report feeling more tired, especially in the first days. No trial has quantified it.

The effects the trials did not measure

Sleep

Sleep disruption is the most consistent complaint in community reports that does not appear in the trial literature, almost always tied to taking NMN or NR in the afternoon or evening. No trial has recorded a sleep outcome, so this is unverified. The proposed explanation, that NAD+ is tied to the circadian clock through the sirtuin SIRT1 and that raising it late in the day sends a daytime signal, is plausible and untested. Morning dosing is the practical answer and costs nothing.

Methylation load

This is the theoretical concern most discussed by long-term users. NR and NMN are ultimately broken down to nicotinamide, and the body clears excess nicotinamide by attaching a methyl group to it, producing N-methylnicotinamide. Each methyl group comes from S-adenosylmethionine, the same donor used for hundreds of other methylation reactions. The worry is that a large, sustained nicotinamide load could drain methyl capacity, with consequences for homocysteine and for the methylation reactions that depend on it. The mechanism is real. Whether it matters at supplement doses is not established: trials at 1 to 2 g of NR have not reported rising homocysteine, and the one study that looked directly found N-methylnicotinamide rising as expected without a measured downstream problem. Users who pair precursors with a methyl donor such as trimethylglycine are hedging against a plausible risk, not a demonstrated one.

⚠ CLAIM (wellness): NAD+ precursors increase nicotinamide, which is cleared by methylation, and this has been proposed to deplete methyl donors with long-term use. Human trials to date have not shown a clinically meaningful methylation deficit at supplement doses. Basis: Trammell 2016 Nat Commun; Martens 2018 Nat Commun. Lane: educational.

Cancer

The most serious open question, and the one that gets the least airtime. NAD+ is a metabolic fuel, cancer cells are metabolically demanding, and the enzymes that consume NAD+ include ones tumors use. In a 2022 mouse study, nicotinamide riboside increased the growth and brain metastasis of a triple-negative breast cancer line. Other preclinical work points the opposite way, with NAD+ supporting the DNA repair and immune function that suppress tumors. There is no human evidence in either direction, and no trial has enrolled people with active cancer to find out. The responsible reading is that anyone with a current or recent cancer diagnosis should treat NAD+ precursors as a question for their oncologist, not as a supplement to try quietly. This is a genuine contradiction in the science, not a settled risk, and it is a contradiction that has not been tested in the population where it matters.

⚠ CLAIM (wellness): Preclinical evidence on NAD+ precursors and cancer is contradictory, with at least one mouse study showing nicotinamide riboside promoted tumor growth and metastasis and other work suggesting NAD+ supports tumor-suppressing functions. There is no human outcome data. Basis: Maric 2023 Biosens Bioelectron; Rajman 2018 Cell Metab. Lane: educational.

Nicotinamide at high doses

Because precursors become nicotinamide, the safety record of nicotinamide itself is relevant at the top of the dose range. Nicotinamide is safe in ordinary amounts, and in one large trial 1 g a day for a year reduced non-melanoma skin cancers with no meaningful side effects. At multiple grams per day, however, it has been linked to liver stress and to reduced insulin sensitivity in some reports. Supplement doses of NR and NMN do not reach that territory, and degraded NMN, which has turned into nicotinamide on the shelf, does not either. The point is simply that “vitamin B3 is harmless” is true at vitamin doses and less true at pharmacological ones.

Oral NAD+ and liposomal NAD+

Swallowed NAD+ is largely broken down in the digestive tract before it can be absorbed intact, so its side effects are those of the nicotinamide and other fragments it yields. Liposomal oral NAD+ is designed to protect the molecule through the gut; its absorption in humans is still being studied and no published trial establishes it, so its side effect profile is unknown beyond the general observation that products have been on the market for years without reports of harm. Nasal sprays and patches, which make similar delivery claims, are covered in NAD+ nasal spray, patches and liposomal NAD+.

Injected and infused NAD+

IV and subcutaneous NAD+ are the established routes for delivering NAD+ itself, used in clinics for decades, and they have a side effect profile of their own that anyone considering them should know about. The most consistent reports, from both the published pharmacokinetic work and from people who have had infusions, are infusion reactions: chest tightness or pressure, flushing, nausea, abdominal cramping, headache and a feeling of anxiety during the drip. These are strongly rate-dependent, which is why NAD+ infusions are run slowly, sometimes over several hours, and why clinics slow or pause the drip when symptoms appear. Subcutaneous injections are reported to cause injection-site pain, redness and swelling, and less often the same flushing and nausea as the IV route. Community accounts of IV NAD+ are polarized: some people describe days of unusual energy and clarity afterward, others describe the infusion as the most unpleasant hours they have spent in a clinic, and neither report is evidence of anything beyond the experience itself.

The published research on injected NAD+ is thinner than the clinic marketing implies, and none of it is a controlled trial of outcomes. This article does not cover doses or protocols; injected NAD+ is a clinical decision made with a prescriber, and the evidence on it is reviewed separately.

Drug interactions and who should be cautious

Formal interaction studies do not exist, so this is reasoning from mechanism. People on diabetes medication should know that NMN improved insulin sensitivity in one trial and that NR did not in others, so effects on glucose are possible and unpredictable. Anyone taking chemotherapy or targeted cancer drugs falls under the cancer caution above, and should not add an NAD+ precursor without oncology input. People with liver disease should be conservative at the high end of the dose range because of the nicotinamide load. Pregnancy and breastfeeding have no safety data at all. And people with a history of gout sometimes ask, because niacin can raise uric acid; NR and NMN have not been shown to, but they have not been studied for it either.

Bottom line

NMN and NR are well tolerated in every trial that has looked, at doses well above what most products supply, for up to a few months. The real uncertainties are longer-term and mechanistic: methylation, cancer, and what an extra decade of daily use does, none of which has been studied. Take them in the morning, with food, at a dose in the tested range, and treat a cancer history as a reason to ask before you start rather than after.

Educational information only, not medical advice, and not evaluated by the FDA. NAD+ precursors are not a treatment for any disease. Long-term safety beyond a few months has not been established. Do not use if pregnant or breastfeeding. Talk to a clinician before supplementing if you have a current or previous cancer diagnosis, liver disease, diabetes, or take prescription medication. Injected and infused NAD+ are clinical procedures and are not covered here.